Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 7/20 | 0.42 |
| ▸ | PPARA | Q07869 | 7/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5511247 | 0.91 | PPARD (0.51) | MAPTTDP1L3MBTL1HPGDPPARD | |
| SCHEMBL5512364 | 0.90 | PPARD (0.49) | MAPTTDP1L3MBTL1HPGDPPARD | |
| SCHEMBL5515949 | 0.90 | PPARD (0.56) | PPARDPPARAPPARG | |
| SCHEMBL5514519 | 0.81 | PPARD (0.59) | MAPTTDP1L3MBTL1HPGDPPARD | |
| SCHEMBL5519896 | 0.80 | PPARD (0.65) | PPARDPPARAPPARG | |
| SCHEMBL5507474 | 0.80 | PPARD (0.64) | MAPTTDP1L3MBTL1HPGDPPARD | |
| SCHEMBL5507935 | 0.79 | MAPT (0.48) | MAPTTDP1L3MBTL1HPGDPPARD | |
| SCHEMBL5512007 | 0.79 | PPARD (0.61) | PPARDPPARAPPARG | |
| SCHEMBL5520230 | 0.79 | PPARD (0.61) | PPARDPPARAPPARG | |
| SCHEMBL5512872 | 0.76 | HPGD (0.43) | MAPTL3MBTL1HPGDPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39916-E1 | Compounds that modulate PPAR activity and methods for their preparation | WARNER LAMBERT COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-RE39916-E1 | Compounds that modulate PPAR activity and methods for their preparation | WARNER LAMBERT COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-RE39916-E1 | Compounds that modulate PPAR activity and methods for their preparation | WARNER LAMBERT COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-6964983-B2 | Compounds that modulate PPAR activity and methods for their preparation | WARNER-LAMBERT COMPANY, LLC (US) | 2005-11-15 | — | — | US | disclosed |
| US-6939875-B2 | Carbocyclic oxy sulfides such as [4-(Biphenyl-4-ylmethylsulfanyl)-5-methoxy-2-methyl-phenoxy]-acetic acid, used to control peroxisome proliferator activated receptors (PPAR), for prophylaxis of metabolic disorders | WARNER-LAMBERT COMPANY (US) | 2005-09-06 | — | — | US | disclosed |
| US-20050153996-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | AUERBACH BRUCE J (US) | 2005-07-14 | — | — | US | disclosed |
| US-20050113440-A1 | Compounds that modulate PPAR activity and methods for their preparation | AUERBACH BRUCE J (US) | 2005-05-26 | — | — | US | disclosed |
| EP-1494989-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20030225158-A1 | Compounds that modulate PPAR activity and methods for their preparation | WARNER-LAMBERT COMPANY | 2003-12-04 | — | — | US | disclosed |
| WO-2003084916-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225158-A1 | Compounds that modulate PPAR activity and methods for their preparation | GPR119, PPARA, PPARG | MAPT 4792/4885TDP1 3973/4885L3MBTL1 3408/4885 |
| US-20050113440-A1 | Compounds that modulate PPAR activity and methods for their preparation | GPR119, PPARA, PPARG | MAPT 4792/4885TDP1 3973/4885L3MBTL1 3408/4885 |
| US-20050153996-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | GPR119, PPARA, PPARG | MAPT 4792/4885TDP1 3973/4885L3MBTL1 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.